NanoVibronix Inc.

NASDAQ: NAOV · Real-Time Price · USD
1.08
-0.10 (-8.47%)
At close: May 22, 2025, 3:59 PM
1.19
9.68%
Pre-market: May 23, 2025, 05:14 AM EDT

Company Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.

Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.

The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.

NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

NanoVibronix Inc.
NanoVibronix Inc. logo
Country United States
IPO Date May 28, 2015
Industry Medical - Devices
Sector Healthcare
Employees 31
CEO Brian M. Murphy

Contact Details

Address:
525 Executive Boulevard
Elmsford, New York
United States
Website https://www.nanovibronix.com

Stock Details

Ticker Symbol NAOV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326706
CUSIP Number 63008J108
ISIN Number US63008J6038
Employer ID 00-0000000
SIC Code 3842

Key Executives

Name Position
Brian M. Murphy Chief Executive Officer & Director
Dr. Harold Jacob M.D. Chief Medical Officer
Lindsey Harrison Vice President of Sales

Latest SEC Filings

Date Type Title
May 20, 2025 10-Q Quarterly Report
May 19, 2025 SCHEDULE 13G Filing
May 16, 2025 8-K Current Report
May 16, 2025 424B4 Filing
May 15, 2025 NT 10-Q Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 14, 2025 S-1/A [Amend] Filing
May 12, 2025 S-1/A [Amend] Filing
Apr 29, 2025 S-1/A [Amend] Filing
Apr 22, 2025 S-1/A [Amend] Filing